University of Nebraska
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Nebraska sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).
University of Nebraska: 407 sponsored US clinical trials, 51 recruiting.
University of Nebraska sponsors 407 registered US clinical trials on ClinicalTrials.gov, 51 of them currently recruiting, and 261 completed. 31 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral Arterial Disease, with 7 trials.
Top-decile sponsor footprint
University of Nebraska ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
261 of 332 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
407 total, page 8 of 9
Reducing Blood Pressure in Prehypertensive Older Rural Women Also Known as Wellness for Women: DASHing Toward Health
NCT00580528
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
NCT00499083
VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma
NCT00571493
Vascular Risk After Kidney Transplantation
NCT00374595
Circadian Rhythms of Aqueous Humor Dynamics in Humans
NCT00572936
Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication
NCT00561340
Predicting Insulin Resistance in American Indian Youth
NCT00498030
Validation of Biomarkers of Exposure and Host Response
NCT00468234
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
NCT00254462
Analysis of Lipid Biomarkers of Exposure and Host Response
NCT00493831
Analysis of Aldehyde Biomarkers of Exposure and Host Response
NCT00482690
Effect of Central Corneal Thickness On IOP Using Various Tonometers
NCT00570791
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
NCT00611351
CT Scans in Screening for Lung Cancer in Current and Former Smokers
NCT00625690
Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer
NCT00569543
A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate
NCT00579995
Heart Failure Exercise And Resistance Training Camp (HEART Camp)
NCT01771900
Sitting Postural Control in Infants With Cerebral Palsy
NCT01200927
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
NCT00486356
Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
NCT00482807
Rheumatoid Arthritis Comorbidity: Bone Health in Men and African Americans
NCT00595894
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
NCT00665457
Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
NCT00556933
Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus
NCT00579371
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
NCT00089024
Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer
NCT00082641
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00483561
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
NCT00580047
Comparison of Latanoprost Vs. Timolol
NCT00579969
Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)
NCT00742157
Pre-operative Evaluation of Kidney & Pancreas Transplant Patients
NCT00580437
Fatigue in Breast Cancer: A Behavioral Sleep Intervention
NCT00572416
Pancreatic Cancer Collaborative Registry
NCT00661882
Effect of Exercise on the Disease Activity of Rheumatoid Arthritis
NCT00792675
Effects of Low-Dose Doxycycline on Oral Bone Loss
NCT00066027
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
NCT00080886
Prevention of Osteoporosis in Breast Cancer Survivors
NCT00567606
Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation
NCT00031642
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
NCT00574730
Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone
NCT00579644
Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis
NCT00579878
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
NCT00571662
The Prospective Evaluation of Pancreatic Function in Pancreas Transplant Recipients
NCT00571818
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
NCT00006478
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00007865
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00007852
Idiotype Vaccine After Chemotherapy & Stem Cell Transplantation in Lymphoma With Failed Induction Chemotherapy
NCT00574886
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
NCT00004192
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
NCT00006695
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
NCT00004112
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 52 |
| Phase 3 | 10 |
| Phase 4 | 21 |
Therapeutic Areas
What is open in the University of Nebraska pipeline
51 recruiting of 407 indexed (13% open); 261 completed (64%).
Phase mix: 31 late (III/IV) vs 109 early (I/II) (early-phase heavy).
Top condition: Peripheral Arterial Disease (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Nebraska: open-pipeline peers nationwide
Peers matched on 407 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 407 trials (± recruiting share)
- Case Comprehensive Cancer Center · 407 trials · 14% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this University of Nebraska page
407 registered trials is a research-attention snapshot, not an endorsement of University of Nebraska or any single study.
- 51 of University of Nebraska's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Peripheral Arterial Disease is the condition University of Nebraska studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral Arterial Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Nebraska pipeline card: 407 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.